유도만능줄기세포(iPSC) 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유래 세포 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Induced Pluripotent Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Derived Cell Type, By Application, By End user By Region & Competition, 2020-2030F
상품코드:1703309
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 유도만능줄기세포(iPSC) 시장은 2024년 14억 5,000만 달러로 평가되었고, 예측 기간 동안 강력한 성장세를 보이며 2030년까지 연평균 복합 성장률(CAGR) 9.60%를 보일 것으로 예측됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
14억 5,000만 달러
시장 규모 : 2030년
25억 2,000만 달러
CAGR : 2025-2030년
9.60%
급성장 부문
의약품 개발
최대 시장
북미
iPS 세포 시장은 재생의료 및 세포치료 분야에서 역동적이고 미래지향적인 분야로 부상하고 있으며, iPS 세포는 다능성 상태로 초기화된 성체 세포로 거의 모든 유형의 세포로 분화할 수 있는 능력을 가지고 있습니다. 이러한 고유한 능력으로 인해 iPSC는 치료제 개발 및 생의학 연구 모두에서 중요한 자산이 되고 있습니다.
시장 성장 촉진요인
만성질환 증가
이러한 전략적 방향 전환은 기존 치료법을 대체할 수 있는 지속 가능하고 맞춤 치료법으로서 iPSC 기반 치료법에 대한 신뢰가 높아졌음을 보여줍니다.
주요 시장 이슈
안전과 효과에 대한 우려
주요 시장 동향
개인 맞춤형 의료와 환자 맞춤형 치료의 성장
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
유래 세포 유형별(간세포, 섬유아세포, 각화 세포, 뉴런, 기타)
용도별(의약품 개발, 재생의료, 독성 시험, 조직공학, 세포치료, 질환 모델)
최종사용자별(연구기관, 기타)
기업별(2024년)
지역별
시장 맵
제6장 북미의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 유도만능줄기세포(iPSC) 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제13장 PESTEL 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Axol Bioscience Ltd.
Cynata Therapeutics Limited
Evotec SE
Fate Therapeutics, Inc.
FUJIFILM Cellular Dynamics, Inc.
Ncardia
LizarBio Therapeutics(Pluricell Biotech)
Reprocell USA, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Takara Bio, Inc
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Induced pluripotent stem cells (iPSCs) market was valued at USD 1.45 billion in 2024 and is projected to exhibit strong growth throughout the forecast period, expanding at a compound annual growth rate (CAGR) of 9.60% through 2030.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1.45 Billion
Market Size 2030
USD 2.52 Billion
CAGR 2025-2030
9.60%
Fastest Growing Segment
Drug Development
Largest Market
North America
The iPSCs market has emerged as a dynamic and high-potential segment within the broader regenerative medicine and cell therapy landscape. iPSCs are adult cells reprogrammed to a pluripotent state, enabling them to differentiate into virtually any cell type. This unique capability makes iPSCs a critical asset in both therapeutic development and biomedical research.
Key Market Drivers
Rising Incidence of Chronic Diseases
The global surge in chronic, non-communicable diseases-including cardiovascular diseases, diabetes, neurodegenerative disorders such as Alzheimer's and Parkinson's, and various cancers-is placing significant strain on healthcare systems. These conditions collectively account for approximately 75% of global mortality and represent substantial clinical and economic burdens across both developed and developing regions.
This trend is directly contributing to the accelerated adoption of iPSCs, which offer transformative potential in disease modeling, drug discovery, and regenerative treatment development. Chronic diseases are typically progressive and require long-term, often lifelong, management. Traditional therapies frequently fall short in addressing the root causes or providing curative solutions.
iPSCs, by contrast, enable the regeneration of damaged or diseased tissues using cells derived from the patient, offering a novel therapeutic pathway. Industry research indicates that a significant portion of biopharmaceutical and medtech executives are prioritizing disruptive innovations-such as cell and gene therapies, including CAR-T and CRISPR-over incremental improvements to existing drugs and devices. Notably, 32% of biopharma leaders are focusing on such innovations, while 30% of medtech stakeholders are shifting investment toward breakthrough platforms, with 24% favoring the development of high-risk, high-reward Class III medical devices.
This strategic redirection underlines the growing confidence in iPSC-based therapies as sustainable, personalized alternatives to conventional treatments.
Key Market Challenges
Safety and Efficacy Concerns
Despite the significant promise of iPSCs, safety and efficacy concerns represent major barriers to their widespread clinical adoption. One of the most critical safety risks involves tumorigenesis; iPSCs, when transplanted, have the potential to form teratomas-tumors comprising various cell types-posing serious safety implications for patients.
Additionally, although iPSCs are often derived from a patient's own cells, issues with immune compatibility can still arise. Particularly in allogeneic applications, where donor-derived iPSC therapies are used, the risk of immune rejection remains a concern and must be carefully managed.
Efficacy also presents a key challenge. Demonstrating consistent and meaningful therapeutic outcomes in both preclinical and clinical settings is essential to gain regulatory approval and clinical trust. Long-term efficacy data, especially for chronic and degenerative conditions, are still being established.
Furthermore, the lack of standardized protocols for iPSC generation, differentiation, and quality control contributes to variability in cell quality and function. This inconsistency can impede reproducibility, scalability, and broader commercialization efforts.
Key Market Trends
Growth of Personalized Medicine and Patient-Specific Therapies
The growing shift toward personalized medicine is among the most significant trends shaping the iPSCs market. The ability to develop therapies tailored to individual genetic and immunological profiles is revolutionizing treatment paradigms, especially for chronic and complex diseases.
iPSCs facilitate the creation of patient-specific therapies by reprogramming somatic cells into a pluripotent state. These cells can then be genetically corrected-if necessary-and differentiated into therapeutic cell types. This personalized approach significantly reduces the risk of immune rejection and enhances therapeutic efficacy, offering hope for conditions that were previously considered untreatable.
In addition, iPSCs are enabling the creation of highly accurate disease models that reflect the patient's unique pathology. These models are invaluable for studying disease mechanisms, evaluating drug responses, and designing customized treatment strategies.
By minimizing the likelihood of adverse reactions and improving clinical outcomes, patient-specific iPSC-based therapies are reshaping expectations in regenerative medicine and significantly advancing the frontier of precision healthcare.
Key Market Players
Axol Bioscience Ltd.
Cynata Therapeutics Limited
Evotec SE
Fate Therapeutics, Inc.
FUJIFILM Cellular Dynamics, Inc.
Ncardia
LizarBio Therapeutics (Pluricell Biotech)
Reprocell USA, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Takara Bio, Inc.
Report Scope:
In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Induced Pluripotent Stem Cells Market, By Derived Cell Type:
Hepatocytes
Fibroblasts
Keratinocytes
Neurons
Others
Induced Pluripotent Stem Cells Market, By Application:
Drug Development
Regenerative Medicine
Toxicity Testing
Tissue Engineering
Cell Therapy
Disease Modeling
Induced Pluripotent Stem Cells Market, By End User:
Research Institutions
Other
Induced Pluripotent Stem Cells Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.
Available Customizations:
Global Induced Pluripotent Stem Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Induced Pluripotent Stem Cells Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others)
